• Bioxyne's subsidiary Breathe Life Sciences receives GMP compliance certificates from multiple countries
• Expands Bioxyne's global presence, with focus on European and UK markets
• Positive outlook for FY2026 with continued growth and new market entry

Bioxyne Limited (ASX: BXN) announced that its wholly owned subsidiary Breathe Life Sciences (BLS) has received certificates of GMP compliance under Mutual Recognition Agreements with several countries, including Australia, Singapore, the European Free Trade Association, the European Community, Canada, and the United Kingdom. This certification allows Bioxyne to expand its presence globally, with a particular focus on European and UK markets. The company is pleased to have gained this certification as it moves to grow its business internationally. Bioxyne is positioned for continued growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany, and other EU countries. The company expects to provide guidance for FY2026 in August.

Bioxyne expects to deliver positive guidance for FY2026, driven by continued growth in Australia and entry into new high-growth markets in the UK, Germany, and other EU countries.

Bioxyne is positioned for continued growth in FY2026, with a focus on expanding its business in Australia as well as entering new high-growth opportunity markets including the UK, Germany, and other EU countries.